Privacy rule builds biomedical research bottleneck

September 13, 2004

CONTACT: BOSTON, Sept. 13 - The Privacy Rule implemented as part of the Health Insurance Portability and Accountability Act (HIPAA) of 1996 is constraining researchers in the United States and slowing the progress of a wide range of clinical studies and biomedical research. Unless fundamental rule changes are addressed, many studies may simply move offshore, warns Roberta Ness, M.D., M.P.H., professor and chair of the department of epidemiology at the University of Pittsburgh's Graduate School of Public Health (GSPH).

Dr. Ness is moderating a policy forum discussion on "Confidentiality and HIPAA: What's a Researcher to Do?" today during the annual meeting of the American College of Epidemiology. Scientific sessions take place through Sept. 14 at the Boston Park Plaza Hotel.

"HIPAA has had substantial negative effects on our ability to recruit individuals to participate in research," says Dr. Ness, whose expertise is in women's health-related research, including preeclampsia, ovarian cancer, vaginal microbiology, pelvic inflammatory disease and pregnancy outcomes. "The way that HIPAA has hurt research, I believe, is a classic example of the law of unintended consequences."

The Privacy Rule, which became effective in April 2003, allows patients to have access to their medical records and find out when the records are disclosed, and it restricts what health professionals can do with the information. Those who violate the rule risk large fines, and possibly jail time.

In the past, identifying patients who might potentially benefit from a clinical trial of a new drug or treatment was simply a matter of reviewing medical records for suitable candidates and then contacting them to see whether they would be interested in participating. Under HIPAA regulations, however, patient contacts now must be initiated by their physicians - busy people whose understandable priority is the practice of primary or specialty patient care.

Epidemiologists such as Dr. Ness - and many other scientists and physicians who do clinical research involving human subjects - now must spend months compiling registries of patients who have given their doctors permission to share their medical records with researchers or devising other complicated alternatives.

Some researchers at the University of Pittsburgh do direct mail solicitation for study participants using voter-registration or drivers' license databases. This may work fine for large population studies that seek health trends, but is inefficient for physicians and scientists who want to target a particular group, such as recently diagnosed ovarian cancer patients who have not yet had radiation or chemotherapy treatments, to try an investigational drug.

"What is happening is that the public is losing access to research," said Dr. Ness. "If clinical research becomes too burdensome here, it will be much easier to do it overseas."
Other participants in the HIPAA policy forum are Robert Hardesty, M.D., professor of surgery at the University of Pittsburgh School of Medicine and director of Pitt's Institutional Review Board; Susan Ehringhaus, J.D., the American Association of Medical Colleges;Martha Linet, M.D., M.P.H., National Cancer Institute; and Russell Localio, J.D., University of Pennsylvania.

Founded in 1948 and fully accredited by the Council on Education for Public Health, the University of Pittsburgh Graduate School of Public Health (GSPH) is world-renowned for contributions that have influenced public health practices and medical care for millions of people. One of the top-ranked schools of public health in the United States, GSPH is the only fully-accredited school of public health in the Commonwealth of Pennsylvania, with alumni who are among the leaders in their fields of public health. A member of the Association of Schools of Public Health, GSPH currently ranks third among schools of public health in NIH funding received. The only school of public health in the nation with a chair in minority health, GSPH is a leader in research related to women's health, HIV/AIDS, and human genetics, among others.

For more information about GSPH, visit the Web site at

University of Pittsburgh Medical Center

Related Ovarian Cancer Articles from Brightsurf:

Ovarian cancer cells cooperate to metastasize
In a study on human ovarian cancer cells in mice, Harvard Medical School researchers discovered a transient, cooperative interaction between cell subpopulations that allows otherwise nonmetastatic tumor cells to become aggressive and spread.

Photodynamic therapy used to treat ovarian cancer
Photodynamic therapy (PDT) is one of the most promising methods of treating localized tumors.

Studying the development of ovarian cancer with organoids
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous ovarian cancer in mini-versions, or organoids, of the female reproductive organs of the mouse.

New class of drugs could treat ovarian cancer
A team of researchers across the University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

How to catch ovarian cancer earlier
Ovarian cancer is often diagnosed too late for effective treatment.

New compound could help treat ovarian cancer
Scientists from the University of Sheffield have discovered a compound that could be more effective in treating certain cancers than standard chemotherapy.

Epigenetic markers of ovarian cancer
Insilico Medicine and its collaborators from Johns Hopkins and Insilico Medicine, used an integrated approach by coupling identification of genome-wide expression patterns in multiple cohorts of primary ovarian cancer samples and normal ovarian surface epithelium with innovative computational analysis of gene expression data, leading to the discovery of novel cancer-specific epigenetically silenced genes.

Ovarian cancer statistics, 2018
A new report from the American Cancer Society provides an overview of ovarian cancer occurrence and mortality data.

Ovarian cancer drug shows promise in pancreatic cancer patients with BRCA mutation
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options.

TGen-led study finds potent anti-cancer drug effect in rare ovarian cancer
An anti-cancer drug used to fight leukemia shows promise against a rare and aggressive type of ovarian cancer -- small cell carcinoma of the ovary hypercalcemic type (SCCOHT) -- which strikes young women and girls, according to a study led by the TGen.

Read More: Ovarian Cancer News and Ovarian Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to